Medtech Talk

Julie Allen, principal of Allen Partners, shares insights on how Medtech executives must work to find the right fit and how companies can build their best team.

The experienced CEOs on this panel have authored some of the greatest stories in Medtech. In this discussion, they delve into their approaches to managing start-ups to multi-million – or billion – dollar acquisitions or IPOs. How do they accurately assess a struggling company and direct a team to turn weakness into strength?

Medtronic executive VP Geoff Martha talks with OISTV about how the Medtech giant views robotics, payers, and where health care transformation is the most difficult. The podcast also includes a clip from his keynote interview at the Medtech Conference.

For years, Intuitive Surgical appeared to be the only company capable of cracking the code for medical robotics. But with companies like Medtronic, Stryker, Johnson & Johnson, Google, and others creating their own efforts the sector appears to be stabilizing. Is there room for early-stage entrepreneurs and VC investors in this capital-intensive sector?

After five years and $25 million, Vascular Solutions CEO Howard Root watched a jury confirm what he knew all along. His company had done nothing wrong. In this interview, Root and Mark Duval, who is advising companies in this area but didn’t work with Vascular Solutions, explain what all this means for Medtech executives.

Mark Leahey, CEO and President of MDMA, delivers his “State of the Industry” address on reimbursement, the medical device tax, UnitedHealthcare/Medtronic and a little bit of Presidential Politics.

A recent jury decision cleared Vascular Solutions of charges of improper off-label marketing. Former Acclarent CEO Bill Facteau discusses his indictment in a similar case, the coming court case, and the support he has received.

Abbott’s move to acquire St. Jude demonstrates how Medtronic’s moves toward “Total Solutions” may change the game in Medtech. We’re going to tackle that topic at the June 1 Medtech Conference. Our conference co-chairs discuss that piece of our upcoming agenda as well as our focus on robotics.

Though initially surprised by Medtronic’s move to buy Covidien, Stacy Enxing Seng says she immediately saw the wisdom of the deal and recognized the opportunity for a fresh start. In an interview, Enxing Seng explains why she left, what she’s been doing, and how her new role at Lightstone Ventures fits her vision for Medtech’s future.

Thomas Gunderson watched the Medtech market for over 20 years at Piper Jaffray. Now recently retired, Gunderson explains how innovation in Medtech is changing, what big strategics think, and where Google might fit into the picture.

Cynthia Yee, a principal at Windham Venture Partners, opened her firm’s office in San Francisco. Yee shares her opinions on many medtech questions including 510(k) versus PMA, the power of payers, and how younger professionals view careers in medtech.

The Medtech industry earns only passing grades in the category of product design, according to product development group Nottingham Spirk. But the company hopes to leverage its experience and access to capital to help Medtech start-ups get to the head of the class.

HealthQuest Capital secured a $225 million fund to invest in new health care technologies. Managing Director Garheng Kong, MD, explains the firm’s views on health care, how doctors view new technologies and what competitive volleyball can teach us about venture investing.

Experienced medtech CEO Kerry Pope explains how the Fogarty Institute is building coalitions of corporations and entrepreneurs to create medtech start-ups.

Outset Medical CEO Leslie Trigg brings a career of success in medtech into a new approach to dialysis. Tablo, a sleek device, could enable dialysis companies an easier, cheaper way of providing dialysis to patients.

As CEO, Kevin Hykes led two companies – Visiogen and Cameron Health – to successful acquisitions by strategic acquirers. In this interview, Hykes shares the lessons learned from leading those companies and explains how he’s adapting to life as CEO of an early-stage company.

Justin Klein, MD, JD, sits down with Healthegy TV to provide details on where his firm, New Enterprise Associates, sees the greatest opportunities in Medtech. He also explains how a firm with $3 billion to manage still makes early-stage investments.

For the past two decades, Josh Makower, MD, has sat on the innovator’s side of the table creating innovations and innovators through his work with the Exploramed incu-bator and Stanford Biodesign Program. Now, Makower takes his considerable abilities to New Enterprise Associates, where he’ll invest in medtech companies on behalf of one of the indus-try’s most venerable firms. Hear where he sees op...

Jason Lettman, partner at Lightstone Ventures, set up shop in Ireland after Lightstone closed its debut fund. Hear how he views Medtech from the other side of the Atlantic.

Oculeve, a stealthy start-up with backing from Kleiner, NEA and Versant, opted to sell its neurostim treatment for Dry Eye to Ophthalmology Leader Allergan.

Solace Therapeutics CEO Bill Gruber hopes to repeat the successful exit he helped execute when Hologic paid close to $300 million for his previous company Interlace.

Oxford’s Scott Defelice explains how his company and 3D printing will impact medtech.

Geoff Gurtner, MD, managing partner of TauTona Group, is trying to look differently at how Medtech is created, funded and sold.

Analysts Michael Lachman and Larry Haimovich put down their pens and pick up the mics to discuss the more promising ophthalmology technologies.

Mark Leahey of the MDMA explains how a move against patent troll could cut the legs out from Medtech entrepreneurs and VCs dependent upon IP protection.